These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28270077)

  • 61. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
    Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.
    Ali SM; Stephens PJ; Miller VA; Ross JS; Pal SK
    Eur Urol; 2015 Aug; 68(2):341-3. PubMed ID: 25796537
    [No Abstract]   [Full Text] [Related]  

  • 63. Antitumor effects of an imidazoquinoline in renal cell carcinoma.
    Schwartz MJ; Liu H; Hwang DH; Kawamoto H; Scherr DS
    Urology; 2009 May; 73(5):1156-62. PubMed ID: 19118885
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Targeting mTOR and survivin concurrently potentiates radiation therapy in renal cell carcinoma by suppressing DNA damage repair and amplifying mitotic catastrophe.
    Rachamala HK; Madamsetty VS; Angom RS; Nakka NM; Dutta SK; Wang E; Mukhopadhyay D; Pal K
    J Exp Clin Cancer Res; 2024 Jun; 43(1):159. PubMed ID: 38840237
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
    Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
    Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Induction of apoptosis of RAW 264.7 cells by the cytostatic macrolide apicularen A.
    Hong J; Yamaki K; Ishihara K; Ahn JW; Zee O; Ohuchi K
    J Pharm Pharmacol; 2003 Sep; 55(9):1299-306. PubMed ID: 14604474
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The Evaluation of Effect of Aurora Kinase Inhibitor CCT137690 in Melanoma and Melanoma Cancer Stem Cell.
    Sogutlu F; Kayabasi C; Yelken BO; Asik A; Gasimli R; Kipcak S; Susluer SY; Avci CB; Gunduz C
    Anticancer Agents Med Chem; 2021; 21(12):1564-1574. PubMed ID: 33106151
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells.
    Costa LJ; Gemmill RM; Drabkin HA
    Urology; 2007 Mar; 69(3):596-602. PubMed ID: 17382186
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Silencing Livin induces apoptotic and autophagic cell death, increasing chemotherapeutic sensitivity to cisplatin of renal carcinoma cells.
    Wang Z; Liu S; Ding K; Ding S; Li C; Lu J; Gao D; Zhang T; Bi D
    Tumour Biol; 2016 Nov; 37(11):15133-15143. PubMed ID: 27677286
    [TBL] [Abstract][Full Text] [Related]  

  • 70. PP2AC Level Determines Differential Programming of p38-TSC-mTOR Signaling and Therapeutic Response to p38-Targeted Therapy in Colorectal Cancer.
    Zhang Y; Wang X; Qin X; Wang X; Liu F; White E; Zheng XF
    EBioMedicine; 2015 Dec; 2(12):1944-56. PubMed ID: 26844273
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Saikosaponin-d suppresses cell growth in renal cell carcinoma through EGFR/p38 signaling pathway.
    Cai C; Zhang H; Ou Y; Jiang Y; Zhong D; Qi H; Dang Q
    Neoplasma; 2017; 64(4):518-525. PubMed ID: 28485157
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Resistance to the mTOR inhibitor temsirolimus alters adhesion and migration behavior of renal cell carcinoma cells through an integrin α5- and integrin β3-dependent mechanism.
    Juengel E; Makarević J; Reiter M; Mani J; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
    Neoplasia; 2014 Apr; 16(4):291-300. PubMed ID: 24862756
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Identification of fenoldopam as a novel LSD1 inhibitor to abrogate the proliferation of renal cell carcinoma using drug repurposing strategy.
    Zheng Y; Ma Y; Cao H; Yan L; Gu Y; Ren X; Jiao X; Wan S; Shao F
    Bioorg Chem; 2021 Mar; 108():104561. PubMed ID: 33349457
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Discovery of novel 1H-benzo[d]imidazole-4,7-dione based transglutaminase 2 inhibitors as p53 stabilizing anticancer agents in renal cell carcinoma.
    Kim GR; Kang JH; Kim HJ; Im E; Bae J; Kwon WS; Rha SY; Chung HC; Cho EY; Kim SY; Kim YC
    Bioorg Chem; 2024 Feb; 143():107061. PubMed ID: 38154386
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The indolylcoumarin COUFIN exhibits potent activity against renal carcinoma cells without affecting hematopoietic system.
    Champelovier P; Barbier P; Daras E; Douillard S; Toussaint B; Persoon V; Curri V; Peyrot V; Combes S
    Anticancer Agents Med Chem; 2014; 14(6):862-71. PubMed ID: 24568163
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Antiproliferative effects of CC-8062 and CC-8075 in pancreatic cancer cells.
    Mouratidis PX; Colston KW; Bartlett JB; Muller GW; Man HW; Stirling D; Dalgleish AG
    Pancreas; 2009 Jan; 38(1):78-84. PubMed ID: 19117086
    [TBL] [Abstract][Full Text] [Related]  

  • 77. mTOR Activation Initiates Renal Cell Carcinoma Development by Coordinating ERK and p38MAPK.
    Wu H; He D; Biswas S; Shafiquzzaman M; Zhou X; Charron J; Wang Y; Nayak BK; Habib SL; Liu H; Li B
    Cancer Res; 2021 Jun; 81(12):3174-3186. PubMed ID: 33863779
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Identifying novel targets in renal cell carcinoma: design and synthesis of affinity chromatography reagents.
    Bonnet M; Flanagan JU; Chan DA; Giaccia AJ; Hay MP
    Bioorg Med Chem; 2014 Jan; 22(2):711-20. PubMed ID: 24387866
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Ethanol extract of Patrinia scabiosaefolia induces the death of human renal cell carcinoma 786-O cells via SIRT-1 and mTOR signaling-mediated metabolic disruptions.
    Li Z; Tang Y; Zhu S; Li D; Han X; Gu G; Xing N; Ren J; Guo Z; Jiao W; Yan L; Xu Z; Zhang W
    Oncol Rep; 2018 Feb; 39(2):764-772. PubMed ID: 29251317
    [TBL] [Abstract][Full Text] [Related]  

  • 80. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence.
    Leontieva OV; Blagosklonny MV
    Aging (Albany NY); 2010 Dec; 2(12):924-35. PubMed ID: 21212465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.